Tribune Therapeutics is developing novel medicines to treat patients with fibrotic disease. The medicines target the CCN protein family. The CCN protein family is a group of signaling proteins central to the development of fibrosis; the process of exaggerated scar tissue formation. The most famous protein in the CCN family is CCN2, also known as Connective Tissue Growth Factor (CTGF). However, several of the other CCN family members have also been shown to be important drivers of fibrosis, and thus broader inhibition has a greater anti-fibrotic potential than solely targeting CCN2.
Read more about Tribune Therapeutics and the people behind it.